primary antibodies ifn-γ  (ABclonal Biotechnology)

Journal: Theranostics

Article Title: pH-responsive nano-vaccine combined with anti-PD-1 antibodies for enhanced immunotherapy of breast cancer

doi: 10.7150/thno.107200

Figure Lengend Snippet: Impact of nano-vaccine mediated mouse DC immune responses on primary tumor development. Note: Mice were divided into four groups and received subcutaneous injections of PBS, dPEDE, M32+A, dPEDE-A, and dPEDE-A@M32 on days 0, 7, and 14 in the left flank. On day 21, serum, splenocytes, and iLNs cells were collected to assess the immunological effects of the nano-vaccine. (A) Schematic diagram of the mouse immune model and experimental procedure; (B) FCM analysis of the proportion of CD80 + CD86 + positive DCs extracted from the iLNs of mice in different treatment groups; (C) Percentage of CD40 + positive DCs extracted from the iLNs of mice in different treatment groups; (D) ELISA measurements of TNF-α and IFN-γ levels in the serum of mice from different treatment groups; (E) Schematic diagram of the mouse immune tumor growth model and experimental procedure; (F) In vivo bioluminescence imaging of 4T1-luc tumors, showing three representative mice per group; (G) Tumor growth curves for different treatment groups; (H) Survival curves for different treatment groups. Each group in animal experiments consisted of six mice, and values are presented as mean ± SD, ** p < 0.01, *** p < 0.001.

Article Snippet: The cells or tissues were then incubated overnight at 4 °C with primary antibodies F4/80 (Abcam, ab100790, 1:200), CD8 (MA5-29682, 1:100, Thermo Fisher, USA), IFN-γ (14-7313-81, 1:200, Thermo Fisher, USA), and PD-1 (Abcam, ab214421, 1:200).

Techniques: Enzyme-linked Immunosorbent Assay, In Vivo, Imaging

Journal: Theranostics

Article Title: pH-responsive nano-vaccine combined with anti-PD-1 antibodies for enhanced immunotherapy of breast cancer

doi: 10.7150/thno.107200

Figure Lengend Snippet: Impact of nano-vaccine combined with ICB therapy on BC mice. Note: (A) Immunostaining images of tumor tissues for IFN-γ and PD-1 post-nano-vaccine treatment, bar = 100μm; (B) Schematic diagram of the combined treatment process; (C) Tumor growth curves for the BC mouse groups; (D) Display of tumor volume and mass on day 28 post-treatment in each BC mouse group; (E) Survival curves for the BC mouse groups; (F) Flow cytometer analysis showing the proportion of INFγ + CD8 + T cells, TNF-α + CD8 + T cells, and GzmB + CD8 + T cells in tumor tissues of BC mice across different groups; (G-I) Tumor sections stained with H&E, Ki67, and TUNEL (G), statistical graph of Ki67 positive cells (H), and statistical graph of TUNEL positive cells (I), bar = 50 μm. Each group in animal experiments consisted of six mice, and values are presented as mean ± SD. 'ns' indicates no significant difference between groups, * p < 0.05, ** p <0.01, *** p < 0.001.

Article Snippet: The cells or tissues were then incubated overnight at 4 °C with primary antibodies F4/80 (Abcam, ab100790, 1:200), CD8 (MA5-29682, 1:100, Thermo Fisher, USA), IFN-γ (14-7313-81, 1:200, Thermo Fisher, USA), and PD-1 (Abcam, ab214421, 1:200).

Techniques: Immunostaining, Flow Cytometry, Staining, TUNEL Assay